Navigation Links
SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing

CARLSBAD, Calif., Feb. 6 /PRNewswire/ -- SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, announced today the closing of $13.3 million in Series C financing to fund the development and clinical trials for next-generation hybrid contact lens products and to expand sales and marketing efforts globally.

De Novo Ventures of Palo Alto, CA, led this round as well as SynergEyes' Series B round. Bio-Star Private Equity Fund joined Series A and B investors: Alloy Ventures, Delphi Ventures, InnoCal Venture Capital and Windward Ventures as a new investor.

Based in Carlsbad, CA, SynergEyes has developed a new type of contact lens that combines two materials -- a rigid gas permeable center and a soft, hydrophilic outer skirt. The result is a durable "hybrid" lens for patients seeking crisp, clear vision and the all-day comfort of a soft lens.

"SynergEyes sincerely appreciates the continued commitment of our venture capital partners and their support of the vision and mission of SynergEyes. Their investment will ensure that the millions of patients in need of our technology will have access to the many features and benefits only a hybrid contact lens can offer," said Paul Kammann, CFO of SynergEyes, Inc.

"SynergEyes hybrid contact lenses represent a significant advancement in the contact lens industry and give eye care professionals a one-of-a-kind tool to satisfy one of the largest growing patient categories in the world," said Jim Ham, CEO for SynergEyes, Inc. "SynergEyes has demonstrated substantial revenue growth since market introduction in 2006. Our next-generation products will re-define state-of-the-art in the vision correction industry."

Jay Watkins, managing director of De Novo Ventures, expressed his firm's continued support for SynergEyes: "SynergEyes continues to demonstrate significant progress towards becoming a world-class vision care company. Hybrid contact lenses address a critical patient need and we are extremely pleased to continue our strong partnership with this innovative company."

The newest SynergEyes investor, Bio-Star Private Equity Fund, believes the company has the potential to deliver a truly transformational vision correction product. "During the due diligence process, our firm realized the compelling value proposition SynergEyes offers not only patients, but also eye care practitioners," said Renee Masi, Managing Member of BioStar. "The market potential for a product that can offer all the benefits of a rigid and soft contact lens without any of the disadvantages is tremendous."

Incorporating patented HyperBond(TM) technology and HydrolEyes(TM) surface science, the SynergEyes lenses with FDA market clearance include SynergEyes(R) A for naturally occurring ametropia, targeting patients with astigmatism, current gas permeable lens wearers, and patients demanding optimized vision; the SynergEyes(R) KC for keratoconus; the SynergEyes(R) Multifocal lens for presbyopia; and the SynergEyes(R) PS for post-surgery and post-trauma refractive errors.


    Kellie Kaseburg
    Vice President of Global Marketing

This release was issued through eReleases(TM). For more information, visit

SOURCE SynergEyes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. Atritech Announces Completion of a $22 Million Equity Financing
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... , Nov. 25, 2015 Endo International plc (NASDAQ: ... De Silva , President and CEO, will discuss corporate updates ... in New York on Wednesday, December ... . Click on Investor Relations, and then the link to ... the presentation,s start time to visit the site and download ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The ... perfect dish and pleasing the palates of attendees is of the utmost importance. ... to a seasonal get-together, give these recipes a try this holiday season. , ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Smiles ... of TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of ... of the great success Botox® delivers to those suffering with discomfort, soreness, and pain ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
Breaking Medicine News(10 mins):